Skip to content
10-Q

Quarterly Report

Bone Biologics Corp BBLG BBLGW

0001493152-24-046020

← back to feed
Filed
Nov 14, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Nov 14, 2024 2.46M sh
Current Liabilities Q3 2024 · Sep 30, 2024 $273.4K
Current Liabilities Q3 2024 · Dec 31, 2023 $831.4K
Total Liabilities Q3 2024 · Sep 30, 2024 $273.4K
Total Liabilities Q3 2024 · Dec 31, 2023 $831.4K
Current Assets Q3 2024 · Sep 30, 2024 $4.07M
Current Assets Q3 2024 · Dec 31, 2023 $3.74M
Total Assets Q3 2024 · Sep 30, 2024 $4.07M
Total Assets Q3 2024 · Dec 31, 2023 $3.74M
Shares Diluted restated Q3 2024 · Sep 30, 2023 391.85K sh
Shares Diluted restated Q3 2024 · Sep 30, 2023 197.86K sh
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$7.54M
Stockholders Equity Q3 2024 · Sep 30, 2023 $3.79M
Stockholders Equity Q3 2024 · Jun 30, 2023 $5.69M
Stockholders Equity Q3 2024 · Mar 31, 2023 $2.77M
Stockholders Equity Q3 2024 · Dec 31, 2022 $5.95M
Eps Diluted restated Q3 2024 · Sep 30, 2023 −$4.90
Eps Diluted restated Q3 2024 · Sep 30, 2023 −$37.40
Eps Basic restated Q3 2024 · Sep 30, 2023 −$4.90
Eps Basic restated Q3 2024 · Sep 30, 2023 −$37.40
Sga Expense Q3 2024 · Sep 30, 2023 $506.04K
Sga Expense Q3 2024 · Sep 30, 2023 $1.81M
Rd Expense Q3 2024 · Sep 30, 2023 $1.57M
Rd Expense Q3 2024 · Sep 30, 2023 $6.46M
Net Income Q3 2024 · Sep 30, 2023 −$1.92M
Net Income Q3 2024 · Sep 30, 2023 −$7.4M
Net Income Q3 2024 · Jun 30, 2023 −$1.77M
Net Income Q3 2024 · Mar 31, 2023 −$3.71M
Operating Income Q3 2024 · Sep 30, 2023 −$2.08M
Operating Income Q3 2024 · Sep 30, 2023 −$8.27M